Skip to main content
. Author manuscript; available in PMC: 2017 Apr 15.
Published in final edited form as: Cancer Res. 2016 Feb 15;76(8):2125–2136. doi: 10.1158/0008-5472.CAN-15-1490

Figure 4. Ibrutinib reduces MDSC suppression of T cell proliferation.

Figure 4

DMSO or ibrutinib treated MDSC were co-cultured with anti-CD3/CD28 bead activated T cells labelled with CFSE at a 2:1 ratio. After three days cells were collected and stained with anti-CD8 (A) and anti-CD4 (B) antibodies and proliferation assessed by flow cytometry. Histograms show results from one representative experiment. Bar graphs represent means ± SE from six independent experiments, p< 0.05 for CD8 T cells.